CLDX (Celldex Therapeutics) Margin of Safety % (DCF Dividends Based): N/A (As of Jun. 27, 2026)


CLDX Celldex Therapeutics Inc CLDX
57 GF Score
Price $35.23
GF Value $6.88
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Celldex Therapeutics Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Celldex Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

CLDX vs IMNM, ELVN, VERA: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Celldex Therapeutics's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celldex Therapeutics Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's Margin of Safety % (DCF Dividends Based) falls into.


CLDX
57GF Score
Celldex Therapeutics Inc CLDX
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Celldex Therapeutics (CLDX) Overvalued in 2026?

Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued. The current stock price of $35.23 is trading 412.1% above its estimated GF Value™ of $6.88. GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.

Key valuation signals for CLDX:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $6.88 vs. price of $35.23 (412.1% above fair value)
  • GF Score™: 57/100 with 8 warning signs

No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celldex Therapeutics Business Description

Other Exchanges TCE2:Germany
Address 53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
57GF Score

Get the complete analysis for CLDX

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.23
Price
$6.88
GF Value